Back to Search Start Over

Bovine serum albumin-glutaraldehyde (BioGlue ® ) tissue adhesive versus standard renorrhaphy following renal mass enucleation: a retrospective comparison.

Authors :
Bahouth Z
Moskovitz B
Halachmi S
Nativ O
Source :
Therapeutic advances in urology [Ther Adv Urol] 2017 Feb 01; Vol. 9 (3-4), pp. 67-72. Date of Electronic Publication: 2017 Feb 01 (Print Publication: 2017).
Publication Year :
2017

Abstract

Background: To present the operative and post-operative comparison between patients who underwent tumor-bed closure with sutures compared with bovine serum albumin-glutaraldehyde (BioGlue <superscript>®</superscript> ) tissue sealant only.<br />Methods: We retrospectively analyzed data from our ongoing database of 507 eligible patients who underwent open NSS nephron-sparing surgery in our department between January 1995 and May 2014. Patients had tumor-bed closure with sealant adhesive (255 patients) or standard suture technique (252 patients). Demographic, clinical and perioperative data were compared between the two groups, by Chi-square test or by Fisher-Irwin exact test for categorical variables, and by t test for differences in means or by Wilcoxon rank sum test for continuous variables. A multivariate analysis was also done.<br />Results: Patients' baseline characteristics showed similar distribution of the analyzed parameters among both groups, with few differences: younger age in the sealant group (65.4 versus 68.4 years, p = 0.01) and slightly larger mass size in the suture group (4.0 versus 3.9 cm, p = 0.03). Ischemia time was significantly shorter in the sealant group (21.8 versus 27.0 minutes, p = 0001). Blood loss and transfusion rate (0.8% versus 11.9%, p = 0.0001) were significantly less in the sealant group. A multivariate analysis showed date of surgery and blood loss as the major parameters affecting transfusion rate.<br />Conclusions: Closing the tumor bed with BioGlue <superscript>®</superscript> tissue adhesive is feasible, safe, can shorten ischemia time and potentially reduce transfusion rate.<br />Competing Interests: Conflict of interest statement: The authors declare that there is no conflict of interest.

Details

Language :
English
ISSN :
1756-2872
Volume :
9
Issue :
3-4
Database :
MEDLINE
Journal :
Therapeutic advances in urology
Publication Type :
Academic Journal
Accession number :
28392835
Full Text :
https://doi.org/10.1177/1756287217697662